Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 2Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 9Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Mantle-Cell 5Glioblastoma 5Lymphoma, Non-Hodgkin 4Astrocytoma 4Oligodendroglioma 3Multiple Myeloma 3Gliosarcoma 3Central Nervous System Neoplasms 3Brain Neoplasms 3Neoplasms, Plasma Cell 2Lymphoma, Large-Cell, Immunoblastic 2Hodgkin Disease 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Glioma 1Ependymoma 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Cyclophosphamide 9Prednisone 8Etoposide 6Vincristine 5Gemcitabine 5Lenalidomide 4Doxorubicin 4Dexamethasone 3Azacitidine 3liposomal doxorubicin 2endostar protein 2apatinib 2VAP-cyclo protocol 2Ifosfamide 2Cisplatin 2sintilimab 1romidepsin 1ivarmacitinib 1fludarabine phosphate 1fludarabine 1camrelizumab 1Vinorelbine 1Valproic Acid 1Transplantation, Autologous 1TQ-B3525 1Rituximab 1Prednisolone 1Polymerase Chain Reaction 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, T-Cell, Peripheral × Carmustine × Clear all
NCT03629873 2022-01-03

Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
69 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡